All Industries

Tembo e-LV $838 Million SPAC IPO Set To Unlock Shareholder Value For VivoPower (NASDAQ:VVPR)

VVPR

As the world’s shift to EVs gathers more pace and the market rebounds from short term demand weakness, one company that has attracted significant investor interest is VivoPower International PLC (NASDAQ:VVPR). The sustainable energy solutions company, which provides conversion kits containing all the parts needed to convert a vehicle from an internal combustion engine to electric, has seen its share price rise based on a number of tailwinds. For starters, VivoPower subsidiary Tembo E-LV revealed that it would be going public by merging with Cactus Acquisition Corp. (NASDAQ:CCTS), a SPAC, in a deal with a pre-money indicative valuation of $838 million. CCTS will issue 83.8 million shares in exchange for Tembo shares at $10 per CCTS share. In addition to that, a special dividend of a total of 16.76 million Tembo shares, or about 20% of the 83.8 million shares, will be distributed to VivoPower International PLC (NASDAQ:VVPR) shareholders, who will receive five Tembo Group shares for each VivoPower share held. According to the most recent quarterly filing, CCTS has $25 million in cash on its balance sheet. If everything plays out as expected, then this deal would unlock massive value for VivoPower shareholders. That is because VivoPwer bought Tembo for about $7.1 million in cash back in 2021, and this deal values it at more than 120x. This deal has not only illustrated the leadership’s commitment to increasing shareholder value but also the market’s willingness to pay a premium for EV companies solving the EV problem in a different way. Although VivoPower International PLC (NASDAQ:VVPR) stock has already rallied significantly, it is clear that there is still more room for upside. Just to recap, here’s a simple breakdown of the deal and how it would translate to a higher share price for VivoPower shareholders. VivoPower International PLC (NASDAQ:VVPR) shareholders get 5 Tembo shares worth $10 for every share held. Assuming a conservative scenario where the IPO raises only 10% of $838 million, that would translate to at least $83.8 million in market cap for vivo power. VivoPower has about 3.5 million shares outstanding, which would translate into a share price of roughly $23. That means that VivoPower could make investors triple-digit returns once this deal closes, and that is without taking into account the dividend shares. At $1 per dividend share, that would translate to an additional $5 per share held for VivoPower shareholders. Ultimately, even if the Tembo share price upon IPO is only $1, that would imply that VVPR shares are worth $28, including the value of dividend shares. To further illustrate the upside potential in the VivoPower International PLC (NASDAQ:VVPR) stock, consider this: The company recently received a $10 million direct investment from an Emirati based family office associated with the ruling family of Dubai, at a $120 million pre-money valuation. Based on this fact, the value per share of VVPR could be $40 per share. Share buyback and restructuring Another important tailwind that has contributed to sending VivoPower's share price higher is the company's recent announcement that its board had authorized a capital management strategy including a stock buyback program that would allow the company to purchase up to $5 million of its outstanding shares. These buybacks would be funded using the company’s proceeds from the sale of businesses and asset divestitures, including spin-offs like the Caret business unit’s portfolio. The Caret business unit’s portfolio represents up to ten solar projects totaling 586 MW-DC at varying stages of development. Last week, VivoPower International PLC (NASDAQ:VVPR) also announced that it entered into a definitive asset sale agreement for the sale of one of its non-core business units, Kenshaw Electrical, to ARA Group Limited, a leading diversified industrial services group based in Australia, for a total of A$5 million. Exploding addressable markets VVPR is well positioned to capitalize on the increasing demand for EVs in some of the fastest growing markets right now like southeast Asia, the middle east and Africa. According to Mordor Intelligence, the Middle East and Africa EV markets were valued at about $3.33 billion in 2024 and are expected to be worth $9.42 billion by 2029, representing a CAGR of 23.20%. Tembo’s conversion kits have attracted substantial traction among consumers, as illustrated by the company securing a commitment of 5000+ kits and an order pipeline of 10,000+ in 2023. Those included an MOU in Jordan for 1,000 kits, opening a path to the Middle East, which is the largest Landcruiser market, and a definitive agreement in Kenya for 4,000 kits, providing entry into second-hand vehicle segments. Furthermore, Tembo signed a definitive joint venture agreement with Francisco Motor Corporation to develop and supply electric utility vehicle electrification kits for a new generation of electric jeepneys (e-jeepneys) in the Philippines. This is another significant growth opportunity, considering that the Electric Vehicle Association of the Philippines (EVAP) estimates that the cumulative sales of e-vehicles in the country will reach 6.6 million units by 2030, driven by favorable government policies. In fact, e-vehicles are now exempt from excise tax, and a recent Executive Order scrapped the tariff rates of completely built-up imported e-vehicles for five years to help them become more cost-competitive in the country. Takeaway Going forward, it's clear that VivoPower International PLC (NASDAQ:VVPR) has bright prospects ahead, as illustrated by the fact that according to a release May 6, executive chairman and CEO Kevin Chin again increased his individual shareholding in the company by adding an additional 100,000 shares (about 2.7% of the outstanding shares) to increase his shareholding to 13.5%, signaling his confidence in the company. For more information, please visit https://vivopower.com/ Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained by VivoPower International to assist in the production and distribution of content related VVPR. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorPitch.com

May 07, 2024 09:00 AM Eastern Daylight Time

Image

InMed (NASDAQ: INM) Developing Cannabinoids Analogs To Treat Alzheimer's – New Studies Showcase INM-901's Therapeutic Abilities

Benzinga

By Meg Flippin, Benzinga Whether due to an aging population or overall population growth, cases of Alzheimer's are increasing. As it stands, nearly seven million Americans suffer from this disease that attacks memory and cognitive functions. By 2050, that’s forecast to reach close to 13 million people. The costs associated with treating Alzheimer's and dementia are projected to swell to $1 trillion by 2050 from $360 billion today. Alzheimer’s is the fifth leading cause of death for people 65 and older. There are several treatments on the market, but they focus on addressing the symptoms rather than repairing and regenerating the damaged neurons. Some drugs and treatments may slow the progression of cognitive decline, but none can reverse the effects of Alzheimer’s. That may change thanks to companies like InMed Pharmaceuticals Inc. (NASDAQ: INM). The leader in cannabinoid and cannabinoid analogs pharmaceutical research, development, manufacturing and commercialization has identified a rare cannabinoid to treat Alzheimer’s. Named INM-901 and based on early preclinical research, the cannabinoid analog showed potential to target several biological pathways associated with Alzheimer’s, providing neuroprotection to the brain neurons and improving neuronal function. Fighting Alzheimer’s With Cannabinoids Recent in vivo studies have shown that INM-901 can improve cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function. INM-901 also displayed neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study. Most recently, the company announced additional preclinical data demonstrating INM-901’s positive pharmacological effects. Several preclinical studies that were conducted in well-characterized Alzheimer’s models demonstrated that INM-901 was able to reduce neuroinflammation and improve neuronal function. The company said the studies also supported the observations made in previously released behavior studies in which locomotor activity, cognition and memory were improved. As a result of these studies, InMed said it plans to accelerate the development of its Alzheimer’s program. Currently, long-term behavioral and mechanism of action / receptor interaction studies are underway with data read-out expected in the third quarter. Meanwhile, InMed said the development of the chemistry, manufacturing and controls (CMC) for drug substance and oral drug product formulation are on-going. “The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD,” said Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed. “There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis.” Multiple Mechanisms Of Action InMed said it is particularly encouraged that INM-901 has multiple potential ways of impacting the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors and the peroxisome proliferator-activated receptor (PPAR) signaling pathway. CB1 and CB2 receptors are part of the endocannabinoid system and are found throughout the body, including in the brain. CB1 receptors are primarily located in the central nervous system, particularly in areas involved in memory, cognition and motor function. CB2 receptors are involved in modulating neuroinflammation and immune responses. Activation of CB1 and CB2 receptors has been shown to help protect brain cells from damage and death. In Alzheimer’s where neuronal death is a hallmark feature, enhancing the activity of these receptors may help to slow down the progression of the disease, reports InMed. Activation of these receptors and other cellular receptors has also been shown to have an impact on neuroinflammation, which is believed to contribute to the progression of Alzheimer’s. As a result, InMed believes INM-901 could offer novel therapeutic strategies for the treatment of this devastating condition. Adding To Its Expertise To further develop INM-901, InMed is deepening its pedigree, and it recently added Dr. David G. Morgan, a renowned leader in neurodegenerative disease, to its Scientific Advisory Board. This reinforces InMed’s commitment to advancing its INM-901 program for the treatment of Alzheimer’s disease. Morgan is the director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. His research interests are Alzheimer’s disease, aging and brain function. He is internationally recognized for his work on immunotherapy and gene therapy to treat Alzheimer-related pathologies. “We are privileged to welcome someone of Dr. Morgan’s stature to our SAB, which underscores the recent progress we’ve achieved in the INM-901 program. Dr. Morgan’s significant contributions and pioneering breakthroughs have made him a leading authority in Alzheimer’s research. His guidance and expertise will be invaluable as we advance to the next stages of development of our INM-901 program in the treatment of Alzheimer’s,” said Hsu. The number of Alzheimer’s cases is set to soar in the years to come as the population ages. InMed wants to slow that, and is betting INM-901 can help. So far studies are backing that up, with more data to come this year. Featured photo by Natasha Connell on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 07, 2024 09:00 AM Eastern Daylight Time

Image

Crypto Oasis Thrives: UAE Blockchain Ecosystem sees Exponential Growth with 2,040 Active Organizations in Q1 2024

Plato AI

Dubai, UAE, May 7th, 2024 - ( (PlatoAI via 500NewsWire) -- Crypto Oasis proudly presented the an update on the ever-evolving UAE blockchain ecosystem during the second edition of Dubai FinTech Summit 2024. Over the past year, The number of active companies has surged from 1,800 to 2,040, marking a significant 13.3% YoY increase. This growth is a testament to the robustness and innovation within the industry, which now has over 10,600 professionals, with a healthy mix of 71% native Blockchain organizations and 29% non-native companies contributing to the ecosystem. The UAE Ecosystem proves to be a hub for innovation and a magnet for attracting talent with over 10,600 individuals now working in the space. Key Highlights: ● Active companies within the ecosystem surged by a significant 13% year-on-year, reaching a staggering record of 2,040 organizations. ● Marked increase in the industry workforce, with over 10,600 individuals working in the Blockchain space. ● Regulatory clarity drives crypto industry growth as major global names such as Binance, Bybit, and OKX receive Virtual Asset Service Provider (VASP) licenses from VARA. Within the vibrant UAE blockchain ecosystem, a diverse array of organizations contributes to its continuous success. Traders, brokers, and asset managers form a significant segment, accounting for 20.6%. Close behind, 19.9% are dedicated to technology and advisory services. NFT platforms represent 6.9%, while venture capitalists (VCs) make up 5.3%. The metaverse has a growing presence with 3.7%, and Web3 gaming initiatives account for 3.1%. Additionally, tokenization platforms are carving out a niche, representing 1.5% of the Blockchain organisations in the country. The past year has been pivotal for the UAE blockchain space, with notable developments that have solidified its position as a global leader in blockchain innovation and disruption. VARA, the Virtual Asset Regulatory Authority, has demonstrated a commitment to responsible growth and intends to secure the market’s integrity. Regulatory tailwinds have helped establish the region as a welcoming hub for blockchain enterprises. Binance, Fasset, Hex Trust, Komainu and OKX are among the global crypto service providers to receive the VASP (Virtual Asset Service Provider) license from VARA last year. Regulatory milestones include, Aquanow, Bybit, Crypto.com and Deribit receiving preliminary licenses from VARA. Throughout 2023, the UAE has seen a significant increase in cryptocurrency adoption, reinforcing its status as a burgeoning centre for digital finance. The XRP token from Ripple has been approved under the Dubai Financial Services Authority (DFSA) and Iota, an open-source distributed ledger focused on the Internet of Things (IoT) announced the creation of the Iota Ecosystem DLT Foundation in Abu Dhabi Global Markets (ADGM). Furthermore, the launch of the Dubai Web3 and AI Campus at the DIFC last year has positioned the UAE at the forefront of technological convergence, attracting talent and investment from across the globe. Other blockchain-related news that shows the ecosystem’s remarkable growth trajectory is the fact that the UAE-based Bitcoin miner Phoenix Group became the first crypto-related firm to go public on the Abu Dhabi Securities Exchange at the end of 2023. DFINITY, a Layer 1 protocol, set up their regional hub, ICP.Hub GCC, is an initiative to provide an access point for projects and developers in the region into the Internet Computer Protocols Ecosystem. The UAE has also become home to landmark blockchain events like Ripple Swell and Cardano Summit in November last year, underscoring the country's status as a premier destination for global Blockchain discourse. TOKEN2049, a global conference series, had a premier blockchain event in Dubai in April this year with over 400 side events and over 20,000 attendees. The Dubai AI & Web3 Festival planned for September 11-12, 2024 will be another feather in the cap of the city, as it posed to attract top global thought leaders to discuss the future of the Web3 and AI industry. Ralf Glabischnig, co-founder of the Crypto Oasis said: "The Crypto landscape in the UAE and Middle East region is the fastest growing ecosystem worldwide. The government is doing for Blockchain what Silicon Valley did for tech. This past year has been nothing short of phenomenal for the Crypto Oasis Ecosystem. The surge in companies and talent underscores the UAE's commitment to fostering a vibrant blockchain and Web3 environment. We're excited to witness the continued growth and innovative solutions emerging from this dynamic ecosystem." With a talented workforce and a commitment to innovation, the Crypto Oasis is poised to continue its exceptional progress. The Dubai FinTech Summit was a prime opportunity to witness the UAE's flourishing Blockchain ecosystem firsthand and to present the growth numbers of the ecosystem. About Crypto Oasis The Crypto Oasis is the largest Web3 ecosystem in the world focused on the Middle East and Africa region and is supported by initiators of the Crypto Valley Switzerland. The core elements needed for its development are Talent, Capital, and Infrastructure. The Ecosystem's stakeholders include Investors & Collectors, Start-Ups & Projects, Corporates, Education & Research Institutions, Service Providers, and Government Entities & Associations. Crypto Oasis is the leading Blockchain ecosystem in the world. Today it is the fastest growing, with more than 2,040 blockchain-related organizations in the UAE alone. www.Cryptooasis.ae Contact Details Crypto Oasis Faisal Zaidi +971 55 200 0840 faisal@Cryptooasis.ae Company Website https://cryptooasis.ae/

May 07, 2024 08:58 AM Eastern Daylight Time

Image

Bitget PoolX Announces Listing of MODE (MODE)

Bitget

Bitget, a leading cryptocurrency exchange and Web3 company, is thrilled to announce the listing of MODE (MODE) on its innovative stake-to-mine platform, PoolX. MODE, short for Modular DeFi L2, is a pioneering project backed by Optimism, aimed at revolutionizing decentralized finance (DeFi) on layer 2 solutions. PoolX, Bitget's latest offering, enables users to stake specific coins to potentially earn popular tokens. Each project on PoolX features one or more mining pools, with token rewards distributed hourly based on participants' staking volume. With the addition of MODE to its portfolio, Bitget continues to expand its range of offerings, providing users with access to quality projects in the crypto space. Mode 's mission is to empower developers and users to build and participate in a thriving ecosystem of world-class applications while being directly rewarded for their contributions. As a Modular DeFi L2, Mode aims to build new on-chain economic systems that enable developers to scale their applications. One of Mode's key features is its ease of use for developers. If you have ever deployed to any Ethereum Virtual Machine (EVM) chain, you can deploy to Mode quickly and easily. Developers can build experimental DeFi applications on Mode, receiving hands-on support to scale their projects and earn predictable rewards through sequencer fee sharing and developer airdrops. "We are excited to welcome MODE to the Bitget PoolX platform," said Gracy Chen, Managing Director at Bitget. "MODE's innovative approach to decentralized finance aligns perfectly with our mission to provide our users with access to cutting-edge projects. We look forward to the impact that MODE will bring to the DeFi ecosystem." At PoolX, hourly snapshots of staked amounts will be taken to ensure accurate calculations of users' proportionate shares and rewards. Each mining pool on PoolX calculates its Annual Percentage Rate (APR) separately, providing users with diverse opportunities to maximize their token earnings. Furthermore, users enjoy the flexibility to redeem the staked tokens at any time, with staked assets automatically returning to their spot accounts after the mining period ends. About Bitget Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 25 million users in 100+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions. Formerly known as BitKeep, Bitget Wallet is a world-class multi-chain crypto wallet that offers an array of comprehensive Web3 solutions and features including wallet functionality, swap, NFT Marketplace, DApp browser, and more. Bitget inspires individuals to embrace crypto through collaborations with credible partners, including legendary Argentinian footballer Lionel Messi and official eSports events organizer PGL. For more information, users can visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet Contact Details Bitget Rachel Cheung media@bitget.com Company Website https://www.bitget.com/

May 07, 2024 08:54 AM Eastern Daylight Time

New Study Shows Cardio Diagnostics’ (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more precise, has announced the publication of results from a budget impact modeling study for one of its leading clinical products. PrecisionCHD is an integrated genetic-epigenetic test for the detection of coronary heart disease (CHD). The peer-reviewed study, The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs, highlights the test’s promising developments. The study’s PrecisionCHD budget impact model was designed to evaluate the cost savings associated with using PrecisionCHD as the primary method of initial CHD assessment in place of current commonly used tests, including exercise electrocardiograms, coronary computed tomography angiography (CCTA) and angiograms. It considered factors such as the number of tests performed, the cost of each test and the impact of test results on treatment decisions. The results suggest that using PrecisionCHD could lead to significant cost savings for patients, with an estimated $113.6 million saved per year for a plan with one million members. These savings are primarily driven by the lower cost of PrecisionCHD compared to traditional tests, along with the reduced need for additional testing. Further, the model found that cost savings were not sensitive to patient demographics or insurance plan design. Similar results were observed for plans that exclude Medicare enrollees, only include Medicare enrollees (Part B or Medicare Advantage), offer large co-insurance rates and charge larger co-pays. PrecisionCHD is a multiomic DNA test that aids in the detection of stable CHD. The test evaluates six DNA methylation and ten genetic biomarkers and uses a proprietary machine learning model to interpret the genetically contextual methylation signals from these biomarkers. The sensitivity and specificity of this test are 79% and 76%, respectively, with the clinical validation study in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics being recently published in the Journal of American Heart Association. “The data from this study suggests that the broader use of PrecisionCHD as the initial test for detecting coronary heart disease can yield significant savings to payers,” said David Frisvold, PhD, Associate Professor in the Department of Economics at the University of Iowa and lead author of this study. “More importantly, the reported cost savings were shown to be generalizable to various health plans, potentially leading to increased access to care and improved outcomes for patients with CHD.” PrecisionCHD was recently awarded the Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code, 0449U, by the American Medical Association. It became effective on April 1, 2024. PrecisionCHD was also awarded the Innovation Technology contract from Vizient, the United States’ largest group purchasing organization, whose customer base encompasses over 60% of hospitals and 97% of academic medical centers in the country. Increasing Access, Reducing Costs Heart disease remains the leading cause of death among Americans. It is also one of the largest cost centers for payers. If the barriers to obtaining early cardiovascular care persist, the prevalence and costs associated with heart disease will likely increase. Currently, exercise electrocardiogram, CCTA and single photon emission computed tomography (SPECT) are among the initial tests used to diagnose CHD. These tests are resource-intensive, and require expensive infrastructure and specialized personnel, creating inherent barriers to broader adoption, especially in rural America. The continued reliance on these tests as the initial testing mode for CHD diagnosis could lead to higher costs for payers. Some of the current tests also involve risks that are associated with being exposed to radiation and contrast dyes that could affect the health of the patient long term. Cardio Diagnostics says that PrecisionCHD, on the other hand, is a more cost-efficient, highly scalable and less resource-intensive alternative for initial CHD detection testing. Its sensitive and specific performance minimizes the likelihood of false positives and negatives, potentially decreasing the need for costly follow-up tests and procedures. Furthermore, PrecisionCHD can be implemented virtually via telemedicine and at-home for blood sample collection. It can also be deployed in community settings via mobile health clinics as well as in a more traditional provider setting.This multimodal delivery approach means greater access for patients, and Cardio Diagnostics expects potential additional cost savings for payers as well, with earlier detection and management of CHD. “We believe that PrecisionCHD has the potential to revolutionize how coronary heart disease is diagnosed and managed,” said Robert Philibert, MD, PhD, Chief Medical Officer and co-founder of Cardio Diagnostics, and the senior author of the study. “We are confident that PrecisionCHD will drive value for many healthcare stakeholders including the patient, provider and payer.” Optimizing Cost Efficiency Health plans increasingly prioritize precision medicine solutions to enhance patient outcomes and optimize cost-efficiency, reflecting an industry-wide transition from personalized to precision medicine. This evolution is underpinned by integrating genomic, clinical and socio-economic data, enabling healthcare providers to customize treatment approaches and advance therapeutic innovation. Similarly, provider-led health plans face the same challenges in optimizing patient care while reducing unnecessary medical spending. PrecisionCHD stands out as a resource for health insurers and healthcare providers aiming to streamline the management and financial burden of CHD. As health systems increasingly adopt value-based care (VBC) models, the focus is increasingly on achieving superior patient outcomes and improved population health while maintaining cost-effectiveness. Throughout last year, the expansion and refinement of VBC models have underscored a concerted effort among healthcare providers, payers and policymakers to enhance patient care and manage expenses effectively. This strategic alignment with VBC frameworks highlights the significant role of tools like PrecisionCHD. These tools support targeted, data-driven decisions in CHD treatment and management, potentially revolutionizing approaches to healthcare delivery and cost management. Featured photo by Testalize.me on Unsplash Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

May 07, 2024 08:45 AM Eastern Daylight Time

Image

IZEA Reported Q1 Bookings Growth Of 53%

Benzinga

By James Blacker, Benzinga The market for influencer marketing has grown exponentially since its emergence in the mid-2000s and shows no signs of slowing down. A report published by Allied Market Research last year puts the market size at $16.5 billion in 2022. It projects that this will grow to $199.6 billion by 2032 at a compound annual growth rate (CAGR) of 28.6% from 2023 to 2032. According to the report, key factors propelling this explosive growth include authentic engagement, as conventional advertising often fails to engage today’s cynical consumers. Furthermore, traditional advertising techniques such as print and television have lost some of their effectiveness as consumers spend more time online. It notes, however, that this growth could continue to be constrained by regulatory and compliance barriers, as well as concerns over authenticity and saturation. The report identifies several key players in the industry, including public company IZEA Worldwide (NASDAQ: IZEA), as well as private firms Klear, HireInfluence Inc., NeoReach, Mavrck, Traackr, Inc., Aspire, Hypetap, Upfluence and SocialEdge. Potentially positioned to capitalize on the burgeoning influencer marketing scene is industry trailblazer IZEA Worldwide, which announced on Apr. 4 that its Q1 managed services bookings grew 53% year-over-year to $9.3 million. According to IZEA founder and CEO Ted Murphy, this growth was driven by a strong sales pipeline from the fourth quarter of 2023 and a record-setting pipeline in the first quarter of 2024. “More than 90% of the bookings this quarter have been organic, meaning they were not derived from acquisitions but rather from our own internal growth efforts,” Murphy said. “The organic growth of the Q1 pipeline is significant not only in monetary value but also in the sheer increase in the number of opportunities, which aligns with our strategy for diversifying revenue streams,” he added. The company also saw its first-quarter SaaS business exhibit continued recovery following a low point in the third quarter of 2023. At the end of last year, IZEA recorded its highest-ever number of active SaaS customers. This trend continued into 2024, with the highest count of SaaS customers ever. IZEA also reported several interesting updates during the fourth quarter of 2023. In November, IZEA.com reached the 1 million registered user milestone after seeing a sharp increase in signups, which the company attributed largely to the release of FormAI, the company’s suite of AI tools for creators and marketers. Also in November, IZEA announced the launch of the FormAI community showcase, a new module inside of FormAI that serves as a central location to highlight some of the best generative AI artwork produced by IZEA’s community of marketers and creators. In December, the company announced it had acquired advocate marketing platform Zuberance, adding user-generated content and performance-based creator compensation to its suite of software solutions. In the same month, IZEA announced its acquisition of Hoozu, a leading Australian influencer marketing company headquartered in Sydney. The company has implemented a host of new features into its IZEA Flex platform, as well as launching GPT-4 and AI Video Generation Tool in FormAI in IZEA’s Creator Marketplace. “We are excited and optimistic about the years ahead, and believe that IZEA is well positioned to capitalize on global opportunities in the creator economy,” Murphy said. Featured photo by George Milton on Pexels. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 07, 2024 08:30 AM Eastern Daylight Time

Image

Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection

Benzinga

By James Blacker, Benzinga Despite the large numbers of people affected, cancer treatments have largely produced unsatisfactory results to curb the rise in cases. According to the American Cancer Society, more than 2 million new cancer cases are projected to be diagnosed in the United States in 2024, with over 600,000 cancer deaths expected to occur. Cancer is already the second-leading cause of death in the U.S. overall and the leading cause among people under 85, and analysis from Yale Medicine indicates that new cases of cancer are ticking upward. It’s clear the disease remains a formidable challenge, which is driving companies such as California-based biotechnology firm Renovaro Inc. (NASDAQ: RENB) to pioneer groundbreaking solutions to revolutionize diagnostics and offer more efficient treatment. Renovaro’s Mission To Advance Cancer Care Renovaro is on a mission to accelerate precision and offer personalized medicine for longevity. It leverages AI and biotechnology platforms to enable early diagnosis, better-targeted treatments and drug discovery. The company comprises a biotech arm, RenovaroBio, which focuses on advanced cell-gene immunotherapy, and an AI arm, RenovaroCube, which is committed to the early detection of cancer, its recurrence and subsequent treatment. Alliances With Industry Leaders What makes Renovaro’s approach so unique is its AI platform for diagnosis, which was made possible thanks to a strategic alliance with Nvidia Corp. (NASDAQ: NVDA). In August 2023 Renovaro announced its alliance with Nvidia’s Inception program, which allows it to deploy next-generation AI running on Nvidia’s latest chips for greater accuracy in cancer detection. Renovaro also announced in April that it plans to acquire 100% of Dutch health-tech firm Cyclomics, amending its initial agreement to acquire 75% of the company. Once the acquisition is complete, Renovaro will be able to use Cyclomics’ 4 th generation molecular technology, developed in partnership with Oxford Nanopore Technologies PLC (LON: ONT), to identify single cancer DNA molecules from a single vial of blood with nearly 100% accuracy. Introducing Flamingo: A Game-Changer In Multi-Cancer Detection Also in April this year, Renovaro unveiled Flamingo, “a potentially groundbreaking multi-cancer detection model,” according to the company. Flamingo leverages ultra-low pass whole genome sequencing of cell-free DNA (cfDNA), allowing early detection of cancers. While traditional cancer detection methods can fail to identify cancer at an early stage – when treatment is most effective – Flamingo harnesses the power of AI to perform highly accurate analysis of minute amounts of cfDNA data to distinguish cancer from healthy samples. Ultimately, this potentially allows cancer interventions to happen earlier and improves patient outcomes. “[Flamingo] will accelerate our efforts to realize a paradigm shift in cancer detection,” shares RenovaroCube CTO Frank van Asch. “With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 07, 2024 08:25 AM Eastern Daylight Time

Image

mimic joins the race to develop the first AI-driven collaborative robot, as it raises $2.5M

mimic

The race to develop the first commercially available humanoid robot has been primarily concentrated in the US – until now. mimic, a Switzerland-based startup, is challenging US dominance and joining the robotics race to be the first to take a robotic arm and humanoid hand combination to market using generative AI, as it raises a pre-seed round of $2.5M. mimic’s $2.5M round is led by early stage Swiss investor Founderful, together with participation from German-based fund another.vc, UK-based Tiny.vc and an all-star lineup of specialized angel investors. Spinning out from the research university ETH Zurich, mimic was founded by researchers Elvis Nava, Stefan Weirich,Stephan-Daniel Gravert and Benedek Forrai in 2024. The founding team were working at the intersection of robotics and AI under Professor Robert Katzschmann’s Soft Robotic Labs when they became increasingly convinced that the latest developments in large scale generative AI models would upend a multitude of industries, beyond just language and image generation. The team set out to develop a foundation model for robotic manipulation and quickly realized how much value their idea held to revolutionize the way robotics fit into our everyday lives and economy. Today, global labor shortages are rocking businesses across multiple sectors and employers are struggling to find, hire and retain workers. Against the backdrop of a pronounced shift in work preferences, like reduced hours and enhanced flexibility to work from home, labor shortages are especially severe in the case of menial, repetitive, and demanding manual tasks. mimic plans to ease these shortages with dexterous, human-like robotic hands that fit seamlessly into existing manual labor workflows, driven by state-of-the-art AI models trained directly from human demonstrations. “Most use cases are stationary and do not require a full humanoid robot with legs. That’s why we focus data-collection and hardware ingenuity on a universal robotic hand that is compatible with off-the-shelf industrial robotic arms for positioning.” says co-founder Stephan-Daniel Gravert. This solution will enable a robot with humanoid hands to understand and imitate any behavior, simply by watching a human perform it. This marks a departure from conventional robotic solutions, which focus on being purpose-built for narrow use cases. Since each use case requires expensive ad-hoc engineering and comprehensive pre-programmed movements, robots are only able to complete the narrowly specific task they are designed for. In contrast, mimic is developing robots with a unified, general purpose approach to achieve a variety of tasks with a single robot design. “We designed our robot to mimic a human hand so it fits in our world, instead of re-designing the world to fit with our robot,” says co-founder Elvis Nava. mimic’s robots will be powered by a foundation AI model, meaning they will be able to reason and understand the physical world. The downstream effect is that robots can execute tasks with minimal demonstrations and without requiring expensive, complicated programming by engineers for each new task. These robots are designed for any industry employing workers in repetitive but hard-to-automate tasks involving complex motor skills. Already, the team has been approached by a wide range of initial customers, from supermarkets, industrial baking and gastronomy to manufacturing, recycling and pharmaceutical lab automation. “Conventional automation leaves a huge gap of tedious, low to medium volume manual labor tasks that often fall under the table because they are too complex or not economical to automate. For companies from retail to manufacturing, it becomes increasingly harder to find the right staff for these tasks. Taking AI-driven robotic manipulation to the next level, we can now address these challenges with unparalleled flexibility and ease of use”, says co-founder Stefan Weirich. Humanoid AI and robotics companies are exploding in popularity. According to Goldman Sachs, the global market for humanoid robots could reach $38 billion by 2035. mimic is planning to keep ahead of the competition by collaborating closely with industry clients to develop solutions for the real world while staying laser-focused on platform-agnostic manipulation and hands rather than building an entire humanoid robot. Alex Stöckl, founding partner at Founderful, commented: "We were impressed by mimic's technology and vision. We believe that the market for AI driven robots is going to grow exponentially, and we will see these robots gain widespread adoption very soon". Looking forward, the team will spend the coming months further developing their robot and AI model to prepare for mimic’s official product launch this year. “In the robotics space, adopting general-purpose AI techniques can solve a nearly infinite amount of real-world problems. This approach is so far only constrained by the limited availability of robot training data. We are changing that,” says Elvis Nava. About mimic mimic creates practical and intuitive robots that make life easier for everyone. Originating in a cutting-edge research project at ETH Zurich, the team combines expertise across AI research and engineering disciplines, as well as business strategy. mimic builds embodied intelligence scalable AI models for universal robotic manipulation. It's solutions help to intuitively automate the most complex and tedious manual labor tasks from retail to manufacturing. For more information please visit mimic | Embodied Intelligence (mimicrobotics.com) About Founderful Founderful is Switzerland’s leading pre-seed fund. We give every founder our deepest understanding and highest levels of support, and together, we’re building the future of the Swiss startup ecosystem. Contact Details mimic Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.mimicrobotics.com/

May 07, 2024 08:00 AM Eastern Daylight Time

Image

American Aires Inc. Executing a Strategy To Increase Exposure And Drive Sales

AAIRF, EDR, FOX, RUM

In our modern, technologically driven world, the proliferation of electronic devices emitting electromagnetic fields (EMFs) has raised significant concerns. While these EMFs have undoubtedly improved our lives in terms of convenience and connectivity, they also pose unintended health consequences. Scientific studies have shown that EMF radiation exposure can lead to brain inflammation, tissue damage, and the development of various diseases, including neurodegenerative conditions. This correlation between brain electrical activity and cognitive function underscores the potential risks of prolonged EMF exposure. Pioneering Protection Canadian-based nanotechnology company American Aires Inc. (CSE: WIFI) (OTC: AAIRF) has emerged as a pioneer in addressing the harmful effects of EMF radiation. With over 20 years of dedication and at least $20 million invested in research and development, American Aires has developed cutting-edge solutions to mitigate EMF exposure and optimize human health. The cornerstone of American Aires' technology is its proprietary silicon-based resonator, designed to protect against EMF radiation. Unlike traditional methods that aim to block or absorb radiation, American Aires' technology actively modulates EMFs, creating a protective barrier around electronic devices. These sleek and stylish devices provide personal and area protection without the need for a power source, targeting EMR emitted by various consumer electronic devices, including cellphones, computers, baby monitors, and Wi-Fi, including high-speed 5G networks. Scientific Validation The effectiveness of American Aires' microchip in reducing the harmful effects of EMF radiation has been reaffirmed by the scientific community. A recently published study in the Link Journal confirmed the chip's stabilizing capabilities, supported by eight peer-reviewed studies and 25 clinical and scientific reports, validating the technology. This scientific validation underscores the credibility and reliability of American Aires' solutions in the EMF protection space. Recent Exposure American Aires Inc. (OTC: AAIRF) (CSE: WIFI) American Aires has effectively prioritized public education and brand exposure, recognizing the pivotal role they play in expanding its market presence. CEO Josh Bruni's recent appearance on the Fox News Buiness Channel national TV series "Health Uncensored with Dr. Drew" on May 5, 2024, signifies a significant milestone for the company. This appearance provided a substantial platform for American Aires to showcase its innovative solutions to a vast audience. Broadcasting on a reputable network like Fox News (NASDAQ: FOX), which reaches hundreds of millions of households across the nation, underscores the magnitude of this opportunity. By featuring on such a prominent platform, AAIRF aimed to not only educate viewers about the importance of safeguarding against electromagnetic radiation but also to significantly raise awareness about the company and its mission. CEO Josh Bruni's presence on the program further solidified the company's commitment to transparency, education, and promoting awareness of its groundbreaking technology. To watch the segment and learn more about American Aires' innovative solutions, click here. Additionally, AAIRF has expanded its reach through a series of impactful partnerships and alliances. In a recent collaboration with Endeavor Group Holdings (NYSE: EDR ) subsidiary William Morris Endeavor Entertainment (WME), a powerhouse in the entertainment, sports, and fashion industries, American Aires aims to amplify its brand presence and extend its reach. This partnership promises to spotlight the manifold benefits of Aires' wellness and performance optimization solutions, leveraging WME's extensive network of top-tier artists, athletes, and content creators. The company's #airesathletes campaign further demonstrates its commitment to widening and deepening relationships with top athletes and celebrities. Partnering with renowned figures like Tiki Barber, the former NFL running back, American Aires showcases how its technology benefits athletes and consumers alike, promoting optimal performance and rapid recovery. Continuing its trajectory of strategic exposure, AAIRF announced a pivotal collaboration with Rumble Inc. (NASDAQ: RUM), a leading social video platform with a global reach. This partnership builds upon the company's ongoing efforts to amplify its brand presence and reach a wider audience. The groundwork for the Rumble partnership began over the past year, with AAIRF and RUM working together to test the traffic and conversion performance of the video platform. This collaboration paved the way for American Aires to officially launch a pilot test consisting of a paid ad campaign on Rumble. As part of this campaign, one of Rumble's most popular influencers, English comedian, actor, and influencer Russell Brand, with 1.87 million followers on the platform, will read one Aires ad per week over multiple episodes of his show on Rumble. Additionally, Rumble will display pre-roll "run of network" ad placements before or after Brand's shows air during the campaign. Commenting on the significance of this collaboration, American Aires CEO Josh Bruni stated, "It's very significant that this test campaign features Russell Brand. He not only aligns well with the Aires brand but also has a growing global audience through Rumble and across other media platforms that can reach potential Aires customers around the world." Financial Performance American Aires Inc. (OTC: AAIRF) has experienced robust revenue growth, doubling its revenue consistently over the past two years. In the first nine months of 2022 alone, the company generated $5.5 million in revenue, representing a 63% year-over-year increase. With extrapolated growth, American Aires could potentially achieve $10 million in sales in 2023. Moreover, AAIRF boasts superior profit margins, with gross margins averaging about 60%, rivaling top technology companies like Nvidia and Apple. The company reached a significant milestone by achieving positive adjusted EBITDA in its most recent quarter, highlighting its financial strength and growth potential. Furthermore, American Aires continues to demonstrate its industry leadership with recent announcements. The company achieved record Q4 and annual 2023 order volume, coupled with significant EBITDA profitability in Q4. This financial success reflects American Aires' sustained growth trajectory and its commitment to delivering value to shareholders. American Aires Inc. (OTC: AAIRF) (CSE: WIFI) stands at the forefront of the EMF protection and human optimization industries, offering innovative solutions to address the growing concerns surrounding electromagnetic radiation. Recent advancements, strong financial results, partnerships, and scientific validation of its patented technology all contribute to American Aires reaffirming its leadership in enhancing human well-being in a technology-driven world. As the company continues to innovate and expand its reach, it remains a stock to watch for any smart investor. For more information https://airestech.com/ Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained by Clarkham Capital International to assist in the production and distribution of content related to AAIRF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://RazorPitch.com

May 07, 2024 07:00 AM Eastern Daylight Time

Image

1 ... 11 12 13 14 15 ... 3548